Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv obtains Genetic Toxicology Assets from MilliporeSigmas BioReliance® portfolio.

FREMONT, CA: Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, acquires critical genetic toxicology assets from MilliporeSigmas BioReliance® portfolio, including standard operating procedures, stock cultures, historical control data, and client relationships. While Inotiv did not disclose specific financial terms, the transaction is structured as a sales-based royalty arrangement that does not require the Company to make any upfront payments.

Robert Leasure, Jr., President and CEO of Inotiv, comments, "This transaction with MilliporeSigma adds genetic toxicology to our suite of internal capabilities. We now have assembled in-house all of the critical nonclinical services necessary to support our clients goals of advancing to human clinical trials."

MilliporeSigma is ceasing operations in the field of Genetic Toxicology. The agreement with Inotiv is intended to ensure that existing clients receive uninterrupted service. Additionally, Inotiv plans to hire certain MilliporeSigma employees who would have been laid off.

Additionally, Inotiv announces Gopala Krishna, Ph.D., MBA, as Senior Vice President, Genetic Toxicology, to lead the Company's genetic toxicology service offering. Dr. Krishna is a Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences. He has over three decades of experience in the pharmaceutical industry as a nonclinical leader in drug discovery and development at large and small pharmaceutical companies, including Pfizer, Abbott Laboratories, MGI Pharma, Enzon, and Supernus. 

He has also taught Pharmacology and Toxicology at the University of Michigan's School of Public Health in Ann Arbor, MI. He most recently worked at PAREXEL International as a Principal Consultant - Nonclinical. He is currently the President of the Society of Toxicology's National Capital Area Chapter (NCAC). He has been a contributing senior member of the Environmental Mutagenesis and Genomics (Genetic Toxicology) Society (EMGS) for more than 35 years.

“Evaluation of the potential for novel therapeutics to interact with and alter DNA is a key element of the safety assessment of those drug candidates,” says John E. Sagartz, Chief Strategy Officer of Inotiv. “Inotiv historically has relied on other vendors to provide these key assessments. Im excited to announce the addition of the BioReliance® assets and Dr. Krishna, and we look forward to developing the genetic toxicology business. We believe this is another significant milestone for Inotiv and our clients.”

Dr. Krishna comments, “I am delighted to join Inotiv with the task of expanding the service offering to include genotoxicity capabilities and look forward to leveraging the assets of the BioReliance® portfolio to assist our clients in the development of safe novel therapeutics.”

Inotiv intends to lease space near the current MilliporeSigmas facilities in Rockville, Maryland, to support this new offering.